A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
This article was originally published in The Pink Sheet Daily
Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.
You may also be interested in...
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.
In a novel move to overcome the slowdown in outsourcing, small-molecule drug discovery company Evotec has bought asset manager Bionamics to more quickly progress assets originating in German academia.
Lilly lowers expectations for Cymbalta; Celgene’s Abraxane continues with strong sales; Bristol touts the potential of Eliquis and Bydureon, despite slow sales; Ornskov discusses One Shire plan; BioMarin readies fifth compound for the clinic, and more.